 AUSTIN, Texas, July 8, 2021 PRNewswire -- Aeglea BioTherapeutics, Inc. NASDAQ: AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jonathan D. Alspaugh as Chief Financial Officer. 